PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1672835
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1672835
Global Antibiotics Market is estimated to be valued at USD 58.27 Bn in 2025 and is expected to reach USD 83.70 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.3% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 58.27 Bn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 5.30% | 2032 Value Projection: | USD 83.70 Bn |
The global antibiotics market has been witnessing steady growth over the past few decades. Rising prevalence of infectious diseases along with growing antibiotic resistance has considerably fueled the demand for newer and more effective antibiotic drugs. Moreover, increasing healthcare expenditure in developing nations and favorable regulatory environment supporting antibiotic development has further propelled the market growth. However, high development cost of novel antibiotics and lack of innovative pipeline are some of the major challenges restraining market expansion. Overall, the global antibiotics market is expected to witness robust growth in the coming years driven by ongoing R&D for the treatment of drug-resistant infections.
The global antibiotics market is driven by the rising incidence of infectious diseases worldwide and growing antibiotic resistance. According to the World Health Organization, antimicrobial resistance is one of the biggest threats to global health posing a serious economic and development threat. Growing antibiotic resistance has rendered many older antibiotics ineffective against newer pathogenic strains requiring novel treatment options. This is creating significant opportunities for drug makers to develop innovative drugs. However, high costs involved in new drug development and stringent regulatory procedures are major challenges. Moreover, lack of novel antibiotic pipeline and focus on specialty medicines over infectious diseases threatens sustainable growth. However, initiatives supporting antibiotic R&D through public-private partnerships can help overcome these barriers.
Detailed Segmentation-